Myriad Genetics (STU:MYD) Float Percentage Of Total Shares Outstanding: 97.53% (As of Jul. 08, 2026)


STU:MYD Myriad Genetics Inc STU:MYD
49 GF Score
Price €5.09
GF Value €13.17
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Myriad Genetics Float Percentage Of Total Shares Outstanding?

Myriad Genetics STU:MYD -3.92% 49 Float Percentage Of Total Shares Outstanding is 97.53% as of Jul. 08, 2026. GuruFocus rates STU:MYD with a GF Score™ of 49/100 and a GF Value™ of €13.17 (Possible Value Trap). The stock has 5 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Myriad Genetics's float shares is 92.12 Mil. Myriad Genetics's total shares outstanding is 94.45 Mil. Myriad Genetics's float percentage of total shares outstanding is 97.53%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Myriad Genetics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Myriad Genetics's Institutional Ownership is 40.26%.

STU:MYD
49GF Score
Myriad Genetics Inc STU:MYD
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Myriad Genetics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Myriad Genetics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=92.12/94.45
=97.53%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 97.53% mean?
Myriad Genetics (STU:MYD) has a Float Percentage Of Total Shares Outstanding of 97.53% as of Jul. 08, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Myriad Genetics and its competitors.
Is Myriad Genetics' Float Percentage Of Total Shares Outstanding too high?
Myriad Genetics' current Float Percentage Of Total Shares Outstanding is 97.53%. Overall, Myriad Genetics has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Float Percentage Of Total Shares Outstanding compare to FLGT and CSTL?
Myriad Genetics' Float Percentage Of Total Shares Outstanding of 97.53% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Medical Diagnostics & Research company?
A good Float Percentage Of Total Shares Outstanding depends on the Medical Diagnostics & Research industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Myriad Genetics and its competitors. Myriad Genetics's current Float Percentage Of Total Shares Outstanding is 97.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €13.17, compared to a current price of €5.09 — trading 61.3% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 97.53%. Myriad Genetics' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current Float Percentage Of Total Shares Outstanding is 97.53% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Myriad Genetics (STU:MYD) Overvalued in 2026?

Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued. The current stock price of €5.09 is trading 61.3% below its estimated GF Value™ of €13.17. GuruFocus considers Myriad Genetics to be Possible Value Trap.

Key valuation signals for STU:MYD:

  • Float Percentage Of Total Shares Outstanding: 97.53%
  • GF Value™: €13.17 vs. price of €5.09 (61.3% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Myriad Genetics Business Description

Other Exchanges MYGN:USA0K3W:UKMYD:Germany
Address 322 North 2200 West, Salt Lake City, UT, USA, 84116
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
49GF Score

Get the complete analysis for STU:MYD

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.09
Price
€13.17
GF Value